"id","name","instanceType","rationale","description","uuid:ID","label"
"StudyDesign_1","Study Design 1","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","The main design for the study","0aeb634a-5df2-4df6-a65c-933a26a387b7",""
